{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T16:02:19Z","timestamp":1791388939419,"version":"4.3.3"},"reference-count":67,"publisher":"SAGE Publications","issue":"2","license":[{"start":{"date-parts":[[2025,8,9]],"date-time":"2025-08-09T00:00:00Z","timestamp":1754697600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"funder":[{"DOI":"10.13039\/100010996","name":"American Society of Diagnostic and Interventional Nephrology","doi-asserted-by":"publisher","award":["2024 ASDIN Research in Vascular Access Grant"],"award-info":[{"award-number":["2024 ASDIN Research in Vascular Access Grant"]}],"id":[{"id":"10.13039\/100010996","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["J Vasc Access"],"published-print":{"date-parts":[[2026,3]]},"abstract":"<jats:p>Stenosis of vascular accesses, particularly in arteriovenous fistulas and grafts, remains a significant challenge in hemodialysis patients, often leading to access dysfunction and failure. Endovascular interventions, including stent grafts and drug-coated balloons (DCBs), have emerged as key treatment modalities to mitigate restenosis and prolong access patency beyond simple balloon angioplasty. Preclinical evaluation of these devices relies on large animal models to assess safety, effectiveness, and biological responses before clinical application. This review provides a comprehensive analysis of the large animal models used for evaluating endovascular devices in vascular access stenosis, highlighting their advantages, limitations, and translational relevance. Additionally, we summarize premarket approval (PMA) animal studies for seven endovascular devices currently indicated for use in vascular accesses, examining their study designs, key findings, and regulatory considerations. By synthesizing preclinical data, this review aims to inform future research and regulatory strategies for optimizing endovascular therapies in vascular access management.<\/jats:p>","DOI":"10.1177\/11297298251362928","type":"journal-article","created":{"date-parts":[[2025,8,9]],"date-time":"2025-08-09T10:35:41Z","timestamp":1754735741000},"page":"444-455","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":3,"title":["The use of experimental preclinical models in evaluating endovascular interventions for vascular access stenosis: A review"],"prefix":"10.1177","volume":"27","author":[{"given":"Linda B","family":"Liu","sequence":"first","affiliation":[{"name":"Department of Engineering, Wake Forest University, Winston-Salem, NC, USA"},{"name":"Department of Biomedical Engineering, Wake Forest University School of Medicine, Winston-Salem, NC, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shahriar","family":"Moossavi","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Section on Nephrology, Wake Forest University School of Medicine, Winston-Salem, NC, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9719-6382","authenticated-orcid":false,"given":"Saami K","family":"Yazdani","sequence":"additional","affiliation":[{"name":"Department of Engineering, Wake Forest University, Winston-Salem, NC, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2025,8,9]]},"reference":[{"key":"e_1_3_2_2_2","doi-asserted-by":"publisher","DOI":"10.1053\/j.ajkd.2019.12.001"},{"key":"e_1_3_2_3_2","unstructured":"United States Renal Data System. 2024 USRDS annual data report: epidemiology of kidney disease in the United States. Bethesda MD: National Institutes of Health National Institute of Diabetes and Digestive and Kidney Diseases. https:\/\/usrds-adr.niddk.nih.gov\/2024\/ (2024 accessed 3 April 2023)."},{"key":"e_1_3_2_4_2","unstructured":"U.S. Food & Drug Administration. General considerations for animal studies intended to evaluate medical devices - guidance for Industry and Food and Drug Administration staff https:\/\/www.fda.gov\/media\/93963\/download (2023 accessed 11 September 2024)."},{"key":"e_1_3_2_5_2","doi-asserted-by":"publisher","DOI":"10.2174\/1874303X01407010014"},{"key":"e_1_3_2_6_2","doi-asserted-by":"publisher","DOI":"10.1177\/11297298211015069"},{"key":"e_1_3_2_7_2","unstructured":"Bard Peripheral Vascular Inc. FLAIR\u2122 Endovascular Stent Graft [Instructions for Use]. Tempe AZ: Bard Peripheral Vascular Inc. https:\/\/www.accessdata.fda.gov\/cdrh_docs\/pdf6\/p060002c.pdf (2007 accessed 5 June 2024)."},{"key":"e_1_3_2_8_2","unstructured":"W.L. Gore & Associates Inc. GORE\u00ae VIABAHN-Endoprosthesis [Electronic Instructions for Use]. Flagstaff AZ: W.L. Gore & Associates Inc. https:\/\/eifu.goremedical.com\/ (2024 accessed 22 April 2025)."},{"key":"e_1_3_2_9_2","unstructured":"Bard Peripheral Vascular Inc. Fluency\u00ae Plus Endovascular Stent Graft [Instructions for Use]. Tempe AZ: Bard Peripheral Vascular Inc. https:\/\/www.accessdata.fda.gov\/cdrh_docs\/pdf13\/P130029C.pdf (2014 accessed 22 April 2025)."},{"key":"e_1_3_2_10_2","unstructured":"Bard Peripheral Vascular Inc. Covera\u2122 Vascular Covered Stent [Electronic Instructions for Use]. Tempe AZ: Bard Peripheral Vascular Inc. https:\/\/eifu.bd.com\/hcp\/US (2022 accessed 5 June 2024)."},{"key":"e_1_3_2_11_2","unstructured":"Merit Medical Systems Inc. Merit WRAPSODY\u00ae Cell Impermeable Endoprosthesis [Instructions for Use]. South Jordan UT: Merit Medical Systems Inc. https:\/\/www.merit.com\/wp-content\/uploads\/2024\/12\/407739002_002_WRAPSODY-CIE-IFU-WEB.pdf (2024 accessed 22 April 2025)."},{"key":"e_1_3_2_12_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jvir.2019.07.036"},{"key":"e_1_3_2_13_2","doi-asserted-by":"publisher","DOI":"10.3389\/fcvm.2022.947776"},{"key":"e_1_3_2_14_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.96.2.636"},{"key":"e_1_3_2_15_2","unstructured":"Lutonix Inc. Lutonix\u2122 035 Drug Coated Balloon PTA Catheter (Model 9010) [Electronic Instructions for Use]. Tempe AZ: Lutonix Inc. https:\/\/eifu.bd.com\/hcp\/US (2024 accessed 22 April 2025)."},{"key":"e_1_3_2_16_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.addr.2017.05.015"},{"key":"e_1_3_2_17_2","unstructured":"Medtronic Inc. IN.PACT\u2122 AV Paclitaxel-coated PTA Balloon Catheter [Electronic Instructions for Use]. Minneapolis MN: Medtronic Inc. https:\/\/manuals.medtronic.com\/manuals\/main\/en_US\/home\/index (2024 accessed 22 April 2025)."},{"key":"e_1_3_2_18_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.addr.2016.10.003"},{"key":"e_1_3_2_19_2","doi-asserted-by":"publisher","DOI":"10.1067\/mva.1990.24914"},{"key":"e_1_3_2_20_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1051-0443(95)72828-7"},{"key":"e_1_3_2_21_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1051-0443(07)61830-2"},{"key":"e_1_3_2_22_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.aanat.2019.06.002"},{"key":"e_1_3_2_23_2","unstructured":"Bard Peripheral Vascular Inc. Summary of safety and effectiveness data: FLAIR\u2122 Endovascular Stent Graft. P060002 Tempe AZ. https:\/\/www.accessdata.fda.gov\/cdrh_docs\/pdf6\/p060002b.pdf (2007 accessed 5 June 2024)."},{"key":"e_1_3_2_24_2","unstructured":"W.L. Gore & Associates Inc. Summary of safety and effectiveness data: GORE VIABAHN\u00ae Endoprosthesis. P040037. https:\/\/www.accessdata.fda.gov\/cdrh_docs\/pdf4\/p040037b.pdf (2005 accessed 28 August 2024)."},{"key":"e_1_3_2_25_2","unstructured":"W.L. Gore & Associates Inc. Summary of safety and effectiveness data: GORE VIABAHN\u00ae Endoprosthesis. P040037 S007. https:\/\/www.accessdata.fda.gov\/cdrh_docs\/pdf4\/p040037s007b.pdf (2008 accessed 12 March 2025)."},{"key":"e_1_3_2_26_2","unstructured":"W.L. Gore & Associates Inc. Summary of safety and effectiveness data: GORE VIABAHN\u00ae Endoprosthesis. P130006. https:\/\/www.accessdata.fda.gov\/cdrh_docs\/pdf13\/p130006b.pdf (2013 accessed 5 June 2024)."},{"key":"e_1_3_2_27_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0741-5214(99)70114-X"},{"key":"e_1_3_2_28_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jvs.2012.02.030"},{"key":"e_1_3_2_29_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jvs.2007.01.057"},{"key":"e_1_3_2_30_2","unstructured":"Bard Peripheral Vascular Inc. Summary of safety and effectiveness data: Fluency\u00ae Plus Endovascular Stent Graft. P130029. https:\/\/www.accessdata.fda.gov\/cdrh_docs\/pdf13\/P130029B.pdf (2014 accessed 5 June 2024)."},{"key":"e_1_3_2_31_2","unstructured":"Bard Peripheral Vascular Inc. Summary of safety and effectiveness data: COVERA\u2122 Vascular Covered Stent. P170042. https:\/\/www.accessdata.fda.gov\/cdrh_docs\/pdf17\/P170042B.pdf (2018 accessed 5 June 2024)."},{"key":"e_1_3_2_32_2","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/gfm547"},{"key":"e_1_3_2_33_2","doi-asserted-by":"publisher","DOI":"10.1177\/112972980800900105"},{"key":"e_1_3_2_34_2","doi-asserted-by":"publisher","DOI":"10.1038\/ki.2008.379"},{"key":"e_1_3_2_35_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1525-139X.2012.01112.x"},{"key":"e_1_3_2_36_2","doi-asserted-by":"publisher","DOI":"10.1111\/sdi.12045"},{"key":"e_1_3_2_37_2","first-page":"132","article-title":"Vascular, downstream, and pharmacokinetic responses to treatment with a low dose drug-coated balloon in a swine femoral artery model: new DCB assessed in a pig femoral model","volume":"83","author":"Yazdani SK","year":"2014","unstructured":"Yazdani SK, Pacheco E, Nakano M, et al. Vascular, downstream, and pharmacokinetic responses to treatment with a low dose drug-coated balloon in a swine femoral artery model: new DCB assessed in a pig femoral model. Catheter Cardiovasc Interv 2014; 83: 132\u2013140.","journal-title":"Catheter Cardiovasc Interv"},{"key":"e_1_3_2_38_2","unstructured":"Lutonix Inc. Summary of safety and effectiveness data: LUTONIX\u00ae 035 Drug Coated Balloon PTA Catheter. P130024. https:\/\/www.accessdata.fda.gov\/cdrh_docs\/pdf13\/P130024B.pdf (2014 accessed 20 September 2021)."},{"key":"e_1_3_2_39_2","unstructured":"Lutonix Inc. Summary of safety and effectiveness data: LUTONIX\u00ae 035 Drug Coated Balloon PTA Catheter Model 9010. P170003. https:\/\/www.accessdata.fda.gov\/cdrh_docs\/pdf17\/P170003B.pdf (2017 accessed 8 June 2022)."},{"key":"e_1_3_2_40_2","unstructured":"Medtronic Inc. Summary of safety and effectiveness data: IN.PACT\u2122 Admiral\u2122 Paclitaxel-coated Percutaneous Transluminal Angioplasty (PTA) Balloon Catheter. P140010. https:\/\/www.accessdata.fda.gov\/cdrh_docs\/pdf14\/P140010B.pdf (2014 accessed 14 February 2022)."},{"key":"e_1_3_2_41_2","unstructured":"Medtronic Inc. Summary of safety and effectiveness data: IN.PACT\u2122 AV Paclitaxel-coated Percutaneous Transluminal Angioplasty (PTA) Balloon Catheter. P190008. https:\/\/www.accessdata.fda.gov\/cdrh_docs\/pdf19\/P190008b.pdf (2019 accessed 8 September 2021)."},{"key":"e_1_3_2_42_2","doi-asserted-by":"publisher","DOI":"10.1111\/sdi.12407"},{"key":"e_1_3_2_43_2","unstructured":"Merit Medical Systems Inc. Summary of safety and effectiveness data: WRAPSODY\u00ae Cell-Impermeable Endoprosthesis. P240023. https:\/\/www.accessdata.fda.gov\/cdrh_docs\/pdf24\/P240023B.pdf (2024 accessed 23 January 2025)."},{"key":"e_1_3_2_44_2","doi-asserted-by":"publisher","DOI":"10.21037\/cdt-22-497"},{"key":"e_1_3_2_45_2","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.2016050598"},{"key":"e_1_3_2_46_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jss.2006.04.001"},{"key":"e_1_3_2_47_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jvir.2007.10.029"},{"key":"e_1_3_2_48_2","doi-asserted-by":"publisher","DOI":"10.1152\/ajpheart.00650.2007"},{"key":"e_1_3_2_49_2","article-title":"Development of a porcine model of arteriovenous fistula venous stenosis treated with percutaneous transluminal angioplasty","volume":"36","author":"Singh PG","year":"2025","unstructured":"Singh PG, Kilari S, Negm AS, et al. Development of a porcine model of arteriovenous fistula venous stenosis treated with percutaneous transluminal angioplasty. J Vasc Interv Radiol 2025; 36: 332\u2013339.e10.","journal-title":"J Vasc Interv Radiol"},{"key":"e_1_3_2_50_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jvir.2024.12.023"},{"key":"e_1_3_2_51_2","unstructured":"Paul R [Sen.-R-K]. FDA Modernization Act 2.0 https:\/\/www.congress.gov\/bill\/117th-congress\/senate-bill\/5002\/ (2022 accessed 31 March 2025)."},{"key":"e_1_3_2_52_2","doi-asserted-by":"publisher","DOI":"10.1093\/toxsci\/kfae122"},{"key":"e_1_3_2_53_2","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2018.00808"},{"key":"e_1_3_2_54_2","doi-asserted-by":"publisher","DOI":"10.3389\/fmedt.2021.675188"},{"key":"e_1_3_2_55_2","doi-asserted-by":"publisher","DOI":"10.1002\/btm2.10618"},{"key":"e_1_3_2_56_2","doi-asserted-by":"publisher","DOI":"10.1007\/s13239-025-00776-z"},{"key":"e_1_3_2_57_2","doi-asserted-by":"publisher","DOI":"10.1007\/s13239-016-0273-y"},{"key":"e_1_3_2_58_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejpb.2020.09.016"},{"key":"e_1_3_2_59_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0256783"},{"key":"e_1_3_2_60_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.kint.2021.06.009"},{"key":"e_1_3_2_61_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0902045"},{"key":"e_1_3_2_62_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jvs.2016.04.035"},{"key":"e_1_3_2_63_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jvir.2016.06.014"},{"key":"e_1_3_2_64_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jvir.2022.02.008"},{"key":"e_1_3_2_65_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.kint.2023.03.015"},{"key":"e_1_3_2_66_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.kint.2025.01.006"},{"key":"e_1_3_2_67_2","doi-asserted-by":"publisher","DOI":"10.2215\/CJN.14231217"},{"key":"e_1_3_2_68_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1914617"}],"container-title":["The Journal of Vascular Access"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/11297298251362928","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/11297298251362928","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/11297298251362928","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,2]],"date-time":"2026-05-02T03:27:16Z","timestamp":1777692436000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/11297298251362928"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,9]]},"references-count":67,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,3]]}},"alternative-id":["10.1177\/11297298251362928"],"URL":"https:\/\/doi.org\/10.1177\/11297298251362928","relation":{},"ISSN":["1129-7298","1724-6032"],"issn-type":[{"value":"1129-7298","type":"print"},{"value":"1724-6032","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,9]]}}}